Invitae Corporation

NVTA

Börsenwert 25,5 Mio. $

Medical genetics firm Invitae (NYSE: NVTA ) suffered a shocking fall from grace as insider reports point to an upcoming bankruptcy filing. Although the company forwarded a compelling concept — leveraging genetic testing and diagnostics to assess hereditary disease risks — the business model didn't resonate with customers or investors.

Medical test maker Invitae is preparing to file for bankruptcy within weeks, the Wall Street Journal reported on Monday, according to people familiar with the matter.

SAN FRANCISCO , Jan. 30, 2024 /PRNewswire/ -- Invitae  (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.

Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges.

SAN FRANCISCO , Jan. 22, 2024 /PRNewswire/ --  Invitae  (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which include carrier screening and non-invasive prenatal screening, to Natera (NASDAQ: NTRA).  The value of the transaction is up to $52.5 million, including cash, milestone payments and litigation credits.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE: NVTA), a leading medical genetics company, certain assets relating to Invitae's non-invasive prenatal screening and carrier screening business. Natera has made an upfront payment in the amount of $10 million to Invitae. In addition, the transaction includes $42.5 million in potential milestone payments including cash and litigati.

Cathie Wood's ARK Innovation ETF isn't afraid to go against Wall Street and the S&P 500. But in some cases, the consensus agrees with the famed ETF manager.

We have crafted a tree with the most flourishing stocks of 2023 and the ones that are poised to soar in 2024.

Invitae (NVTA) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Chinese stocks are up today and investors wondering why can find out all about these movements with our coverage for Friday! All of this comes from recent data concerning the Chinese economy.